EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo

Jarrett J Adams, Levi L Blazer, Jacky Chung, Minoo Karimi, Taylor Davidson, Bailey Blair, Carlos Waddle, Craig A Hokanson, Heather A Bruce, Alexander U Singer, Eva-Maria Tombak, Kiira Gildemann and 9 more

Protein Science · 2026

DOI: 10.1002/pro.70462 ↗

At a glance

Journal article in Protein Science, 2026. Written by Jarrett J Adams and 20 co-authors. Institution: Anvil Institute for Systems Biologics, Toronto, Ontario, Canada. Major MEDLINE topics: Receptors, Erythropoietin, Erythropoietin, Erythropoiesis, Hematinics. 29 references. The full text is freely available (open access, CC BY 4.0). Funded by: Charles Pak Foundation, NIDDK NIH HHS, NIGMS NIH HHS.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Recent studies have shown that tetravalent antibodies are potent and efficacious agonists of the erythropoietin (EPO) receptor (EPOR) both in vitro and in vivo. To identify antibody‐based erythropoiesis‐stimulating agents (ESAs) with therapeutic potential, we evaluated various tetravalent antibody formats for EPOR agonism and key biophysical properties necessary for biologic drug development. We identified two distinct tetravalent antibody formats that strongly stimulated the growth of UT7/Epo cells, which rely on EPOR signaling for proliferation. Moreover, one of these formats exhibited ideal biophysical characteristics for drug development. This format consisted of a diabody (Db) and two antigen‐binding fragment (Fab) arms fused to the N‐ and C‐termini of an Fc domain, respectively, to form a tetravalent Db‐Fc‐Fab (EPRA‐0322). In a mouse model expressing the human EPOR, EPRA‐0322 induced erythropoiesis with greater potency, efficacy, and duration than darbepoetin, a hyperglycosylated EPO currently used in clinical practice. These findings highlight tetravalent antibodies, and the Db‐Fc‐Fab format in particular, as promising next‐generation ESAs suitable for large‐scale production and clinical use.

Subjects

MeSH terms (MEDLINE)

Receptors, ErythropoietinErythropoietinErythropoiesisHematinicsAnimalsHumansMice

Author keywords

EPOEPORagonistantibodyantibody polymerdiabodydimerdrug designerythropoiesishelical ultrastructureprotein engineering

Substances

Receptors, ErythropoietinErythropoietinHematinics

Authors and institutions

  • Anvil Institute for Systems Biologics, Toronto, Ontario, Canada.
  • EPOK Therapeutics, Toronto, Ontario, Canada.
  • Simisco Biosciences, Hayward, California, USA.
  • Département de Biochimie, Université de Montréal, Montréal, Québec, Canada.
  • Departments of Internal Medicine and Physiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
  • Icosagen, Tartu, Estonia.

Funding

  • Charles Pak Foundation
  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • Canada Foundation for Innovation
  • NIH HHS
  • NHLBI NIH HHS
  • Center of Mineral Metabolism Endowed Professor Collaborative Research Support Grant
  • CIHR

Cite

APA

Adams, J. J., Blazer, L. L., Chung, J., Karimi, M., Davidson, T., Blair, B., Waddle, C., Hokanson, C. A., Bruce, H. A., Singer, A. U., Tombak, E. M., Gildemann, K., Tamberg, N., Kiiver, K., Ustav, M., Ma, Y., Colombo, L., Huang, L. J., Michnick, S. W., …, & Sidhu, S. S. (2026). Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo. Protein Science. https://doi.org/10.1002/pro.70462

Vancouver

Adams JJ, Blazer LL, Chung J, Karimi M, Davidson T, Blair B, et al. Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo. Protein Science. 2026. doi:10.1002/pro.70462

BibTeX
@article{Adams2026,
  author = {Adams, Jarrett J and Blazer, Levi L and Chung, Jacky and Karimi, Minoo and Davidson, Taylor and Blair, Bailey and Waddle, Carlos and Hokanson, Craig A and Bruce, Heather A and Singer, Alexander U and Tombak, Eva-Maria and Gildemann, Kiira and Tamberg, Nele and Kiiver, Kaja and Ustav, Mart and Ma, Yue and Colombo, Luigi and Huang, Lily Jun-Shen and Michnick, Stephen W and Moe, Orson W and Sidhu, Sachdev S},
  title = {Tetravalent antibodies are more potent and efficacious erythropoiesis‐stimulating agents than erythropoietin in vivo},
  journal = {Protein Science},
  year = {2026},
  doi = {10.1002/pro.70462}
}
Start for free →